US-based genomics giant Illumina (NASDAQ: ILMN) has announced a strategic partnership with chip manufacturer NVIDIA (NASDAQ: NVDA) to advance technology platforms for the analysis and interpretation of multiomic data. This collaboration aims to accelerate progress in clinical research, genomics AI development, and drug discovery, leveraging the strengths of both companies to drive innovation in the field of genomics.
Technology Integration and Goals
The partnership will enable the global R&D community to access rich genomic data by integrating NVIDIA RAPIDS accelerated data science software with NVIDIA BioNeMo platform’s generative AI models and fine-tuning capabilities for proprietary datasets. Additionally, the integration will include MONAI for spatial cell imaging workflows. Illumina and NVIDIA will work together to make these advanced tools accessible on the Illumina Connected Analytics platform, enhancing the capabilities of researchers and clinicians worldwide.
Initial Collaboration Focus
In the first phase of the collaboration, Illumina and NVIDIA will focus on enabling DRAGEN algorithms on NVIDIA GPUs. This initiative will significantly enhance the processing power and efficiency of genomic data analysis, providing researchers with faster and more accurate insights into complex biological systems. By combining Illumina’s expertise in genomics with NVIDIA’s leadership in AI and computing, the partnership is poised to transform the landscape of clinical research and drug discovery.-Fineline Info & Tech
